title: Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes. Application for ribozymes that target human t-cell leukemia virus type I tax/rex mRNA.
abstract: We investigated the usefulness of ribozymes in inhibiting the expression of human T-cell leukemia virus type I (HTLV-I) gene. Two hammerhead ribozymes that were against HTLV-I rex (RR) and tax (TR) mRNA were synthesized. Both ribozymes were sequence-specific in the in vitro cleavage analysis of run-off transcripts from tax/rex cDNA. Intracellular activities of the ribozymes were studied in HTLV-I tax cDNA-transfected rat embryonic fibroblasts (Rat/Tax cells), which expressed the Tax but not Rex. Ribozymes were delivered into cells using anionic or cationic liposomes fused with hemagglutinating virus of Japan (HVJ). Cellular uptake of ribozymes complexed with HVJ-cationic liposomes was 15-20 times higher cellular uptake than naked ribozymes, and 4-5 times higher than that of ribozymes complexed with HVJ-anionic liposomes. HVJ-cationic liposomes promoted accumulation of ribozymes in cytoplasm and accelerated transport to the nucleus. Tax protein levels were decreased about 95% and were five times lower when the same amount of TR was introduced into the cells using HVJ-cationic, rather than HVJ-anionic liposomes. Inactive ribozyme and tax antisense oligodeoxynucleotides reduced Tax expression by about 20%, whereas RR and tax sense oligodeoxynucleotides had no effect. These results suggest that the ribozymes' effect against tax mRNA was sequence-specific, and HVJ-cationic liposomes can be useful for intracellular introduction of ribozymes.
authors.affiliation: Department of Laboratory and Molecular Medicine, University of Kagoshima, 8-35-1 Sakuragaoka, Kagoshima 890, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Kitajima
authors.forename: N
authors.initials: N
authors.lastname: Hanyu
authors.forename: Y
authors.initials: Y
authors.lastname: Soejima
authors.forename: R
authors.initials: R
authors.lastname: Hirano
authors.forename: S
authors.initials: S
authors.lastname: Arahira
authors.forename: S
authors.initials: S
authors.lastname: Yamaoka
authors.forename: R
authors.initials: R
authors.lastname: Yamada
authors.forename: I
authors.initials: I
authors.lastname: Maruyama
authors.forename: Y
authors.initials: Y
authors.lastname: Kaneda
mesh_terms: D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D004337:Drug Carriers; D016370:Gene Products, rex / Q000096:biosynthesis / Q000378:metabolism*; D016356:Gene Products, tax / Q000096:biosynthesis / Q000378:metabolism*; D016355:Genes, pX; D015368:Human T-lymphotropic virus 1 / Q000235:genetics*; D006801:Humans; D007700:Kinetics; D008081:Liposomes; D016337:RNA, Catalytic / Q000138:chemical synthesis / Q000378:metabolism* / Q000493:pharmacokinetics; D012333:RNA, Messenger / Q000096:biosynthesis*; D051381:Rats; D011994:Recombinant Proteins / Q000096:biosynthesis; D018108:Respirovirus; D014158:Transcription, Genetic; D014162:Transfection
chemical_list: D004337:Drug Carriers; D016370:Gene Products, rex; D016356:Gene Products, tax; D008081:Liposomes; D016337:RNA, Catalytic; D012333:RNA, Messenger; D011994:Recombinant Proteins